Trial Profile
Phase II trial of eribulin in patients with recurrent glioblastoma (ENIGMA)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jul 2022
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- Acronyms ENIGMA
- 07 Jun 2022 Primary endpoint (One-year survival rate) has been met, according to Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 08 Oct 2021 Status changed from active, no longer recruiting to completed.